Skip to Content
PR Newswire

New Civis Analytics Research Identifies Most Persuasive COVID-19 Vaccine Messaging for Uncertain Americans

New Civis Analytics Research Identifies Most Persuasive COVID-19 Vaccine Messaging for Uncertain Americans

New Civis Analytics Research Identifies Most Persuasive COVID-19 Vaccine Messaging for Uncertain Americans

Findings highlight need for messages grounded in optimism and empathy, not scare tactics

PR Newswire

CHICAGO, May 11, 2021

CHICAGO, May 11, 2021 /PRNewswire/ -- Civis Analytics, a data science firm innovating at the intersection of public good and scientific best practices, today announced findings of an experiment to scientifically determine the most persuasive messaging for Americans most likely to be uncertain about COVID-19 vaccination. The study found that the two most persuasive message themes focused on returning to daily activities and emphasizing personal choice.

To isolate persuasion effects and minimize bias, Civis set up a treatment vs. control trial (the same framework as clinical trials, considered the scientific gold standard for research) using its on-demand Creative Focus tool. Respondents were pre-selected to reflect vaccine hesitant populations, and were shown one of six messages (a control group saw no message):

  • "Vaccine Safety" highlighted the safety of the COVID-19 vaccines: the rigorous FDA process that was followed, the diversity of clinical trial participants, and the rarity of serious side effects.
  • "Getting Back to Normal" emphasized the daily activities that vaccinated individuals can enjoy, and highlighted experiences that may be off-limits to non-vaccinated individuals, such as concerts and international travel.
  • "Personal Story" told the tale of a healthy, 30-year-old woman's battle with COVID, recounting her fear of long-term effects and inability to resume activities like running.
  • "Scary COVID Statistics" focused on the dangers of COVID (even for young adults), and the vaccine's potential to stop these statistics from rising.
  • "Patriotism" positioned the vaccines as an example of American ingenuity, trumpeting vaccination as the ultimate expression of freedom, liberty, and country.
  • "Personal Decision" emphasized that it's normal to have questions about the vaccine, encouraged learning more, and positioned vaccination as a person's individual choice.

Key findings of the experiment include:

  • "Getting Back to Normal" and "Personal Decision" were most persuasive, each increasing likelihood to vaccinate by 5 percentage points (pp) on average. "Safety," "Scary COVID Stats," and "Patriotism" were all ineffective, and "Personal Story" had the highest likelihood of backfiring.
  • These findings largely hold true when broken down by subgroup, but there are a few interesting differences. The "winning" messages were particularly impactful with a few specific groups:
    • "Back to Normal" was especially effective with: men (+7pp); people making incomes over $75k/year (+7pp); Roman Catholics (+8pp); people that get news from public radio, MSNBC, The Wall Street Journal and TikTok (+7pp each); and Black (+6pp), Latino/a (+7pp), and Asian (+7pp) Americans
    • "Personal Decision" was especially effective with: Republicans (+6pp); White Americans (+6pp); people that watch Fox News (+8pp)
  • "Personal Story" backfired among men (-5pp), and had no effect at all among women. Notably, using a personal story was effective in August 2020, but not in this study. Our reasoning for this change is:
    • The specific story was heavier on scare tactics, which we've seen does not work.
    • American society and attitudes toward vaccination have changed.
    • The 2020 test surveyed Americans of all different backgrounds and beliefs. Here, we focused specifically on populations that are likely to be vaccine-hesitant, according to our prior research.

"The results of this experiment provide several high-level recommendations for talking about the COVID-19 vaccines," said Crystal Son, MPH, Director of Healthcare Analytics at Civis Analytics.

"First, lead with a message of hope and optimism, emphasizing that the vaccines are a way to get back to the moments we miss the most, and that forgoing vaccination may mean it takes longer to resume activities," Son said "Second, empathize with concerns, and acknowledge that questions are natural and normal. Encourage people to seek the information they need to make a decision. Finally, be prepared to respond to concerns about safety and side effects with accurate and straightforward responses, but don't lead with messages intended to educate people about safety and correct their beliefs."

To view the full report, visit the Civis Analytics website.

From April 28 to May 3, 2021, 4,215 American adults who belong to one or more "likely to be uncertain" demographic groups1 were randomly shown one of six messages or a control message. Made to Save, a national grassroots effort to ensure communities hardest hit by the pandemic have access to the COVID-19 vaccines and information, provided guidance on message frameworks. After displaying the messages, respondents were asked about their intent to get vaccinated; a statistical model calculated the impact of each treatment compared to the non-treated group, while controlling for respondent characteristics.

About Civis Analytics
Civis Analytics helps leading public and private sector organizations use data to gain a competitive advantage in how they identify, attract, and engage people. With a blend of proprietary data, technology and advisory services, and an interdisciplinary team of data scientists, developers, and survey science experts, Civis helps organizations stop guessing and start using statistical proof to guide decisions. Learn more about Civis at

1 Defined as Black Americans; Latino/a Americans; Americans without a college degree; Americans under the age of 50; Americans making less than $50K/year; and Republicans, per Civis research

View original content to download multimedia:

SOURCE Civis Analytics

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.